

Registration number 5433173

Pharmologic Solutions Limited

Abbreviated accounts

for the year ended 31 March 2011

FRIDAY



A00AJBW2

A37

16/12/2011

#303

COMPANIES HOUSE

Pharmologic Solutions Limited

Contents

	Page
Abbreviated balance sheet	1 - 2
Notes to the financial statements	3 - 5

Pharmologic Solutions Limited

**Abbreviated balance sheet
as at 31 March 2011**

		2011		2010	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	2		113,901		125,468
Current assets					
Stocks		70,415		69,500	
Debtors		33,519		29,827	
Cash at bank and in hand		89		6,701	
		<u>104,023</u>		<u>106,028</u>	
Creditors: amounts falling due within one year		<u>(119,629)</u>		<u>(113,667)</u>	
Net current liabilities			<u>(15,606)</u>		<u>(7,639)</u>
Total assets less current liabilities			98,295		117,829
Creditors: amounts falling due after more than one year			<u>(151,139)</u>		<u>(164,132)</u>
Deficiency of assets			<u>(52,844)</u>		<u>(46,303)</u>
Capital and reserves					
Called up share capital	3		100		100
Profit and loss account			<u>(52,944)</u>		<u>(46,403)</u>
Shareholders' funds			<u>(52,844)</u>		<u>(46,303)</u>

The director's statements required by Sections 475(2) and (3) are shown on the following page which forms part of this Balance Sheet

The notes on pages 3 to 5 form an integral part of these financial statements.

Pharmologic Solutions Limited

Abbreviated balance sheet (continued)

**Director's statements required by Sections 475(2) and (3)
for the year ended 31 March 2011**

In approving these abbreviated accounts as director of the company I hereby confirm

- (a) that for the year stated above the company was entitled to the exemption conferred by Section 477 of the Companies Act 2006 ,
- (b) that no notice has been deposited at the registered office of the company pursuant to Section 476 requesting that an audit be conducted for the year ended 31 March 2011 , and
- (c) that I acknowledge my responsibilities for
 - (1) ensuring that the company keeps accounting records which comply with Section 386 , and
 - (2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Section 393 and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company

These abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies

The abbreviated accounts were approved by the Board on 31 May 2011 and signed on its behalf by

Bhavash Padhiar
Director



Registration number 5433173

The notes on pages 3 to 5 form an integral part of these financial statements.

Pharmologic Solutions Limited

Notes to the abbreviated financial statements for the year ended 31 March 2011

1. Accounting policies

1.1. Accounting convention

The accounts are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

1.2. Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year

1.3. Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows

Leasehold properties	-	Straight line over the life of the lease
Fixtures, fittings and equipment	-	25% reducing balance
Motor vehicles	-	25% reducing balance

1.4. Stock

Stock is valued at the lower of cost and net realisable value

Pharmologic Solutions Limited

Notes to the abbreviated financial statements for the year ended 31 March 2011

continued

1.5. Deferred taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more, or a right to pay less or to receive more, tax, with the following exceptions

Provision is made for tax on gains arising from the revaluation (and similar fair value adjustments) of fixed assets, and gains on disposal of fixed assets that have been rolled over into replacement assets, only to the extent that, at the balance sheet date, there is a binding agreement to dispose of the assets concerned. However, no provision is made where, on the basis of all available evidence at the balance sheet date, it is more likely than not that the taxable gain will be rolled over into replacement assets and charged to tax only where the replacement assets are sold,

Provision is made for deferred tax that would arise on remittance of the retained earnings of overseas subsidiaries, associates and joint ventures only to the extent that, at the balance sheet date, dividends have been accrued as receivable,

Deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted

Deferred tax is measured on an undiscounted basis at the tax rates that are expected to apply in the periods in which timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date

2. Fixed assets	Tangible fixed assets £
Cost	
At 1 April 2010	160,449
At 31 March 2011	160,449
Depreciation	
At 1 April 2010	34,982
Charge for year	11,566
At 31 March 2011	46,548
Net book values	
At 31 March 2011	113,901
At 31 March 2010	125,467

FAILED VALIDATION

Pharmologic Solutions Limited

**Notes to the abbreviated financial statements
for the year ended 31 March 2011**

continued

3. Share capital	2011 £	2010 £
Authorised		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>
Allotted, called up and fully paid		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>
Equity Shares		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>

4. Going concern

The accounts have been prepared on a going concern basis as the director has indicated his willingness to continue to support the company